Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Clinical Response to Rituximab in Recurrent Autoimmune TTP
2010-018794-38Phase 2Active
- Sponsor
- IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rituximab in thrombotic thrombocytopenic purpura (TTP), sponsored by IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico. Primary endpoint: RECURRENCE RATE AT THREE YEARS. Started Jul 2010; status: active.
02
Drugs
rituximab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on 2010-018794-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018794-38.